The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
Radiotherapy (RT) in patients with melanoma historically showed suboptimal results, because the disease is often radioresistant due to various mechanisms such as scavenging free radicals by thiols, pigmentary machinery, or enhanced DNA repair. However, radiotherapy has been utilized as adjuvant ther...
Main Authors: | Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, Dirk Van Gestel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/8/1093 |
Similar Items
-
Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. <i>Cancers</i> 2019, <i>11</i>, 1093
by: Mohammad Krayem, et al.
Published: (2023-12-01) -
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance <break/>Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
by: Mohamad Krayem, et al.
Published: (2020-02-01) -
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
by: Anne Perdrix, et al.
Published: (2017-12-01) -
Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
by: Heike Niessner, et al.
Published: (2022-04-01) -
BRAF<sup>V600E</sup> Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
by: Joonseon Park, et al.
Published: (2023-11-01)